Form 4: Procept BioRobotics Executive Hisham Shiblaq Reports Stock Option Exercise and Sale
SEC Form 4 Filing
Hisham Shiblaq, EVP and Chief Commercial Officer of Procept BioRobotics, exercised stock options and sold shares on June 10, 2024, according to a Form 4 filing.
Summary
- On June 10, 2024, Hisham Shiblaq, EVP and Chief Commercial Officer of Procept BioRobotics, exercised stock options to acquire 26,046 shares of common stock at a price of $4.56 per share.
- Simultaneously, Shiblaq sold 26,046 shares of common stock at a price of $68.2446 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2024.
- Following these transactions, Shiblaq directly owns 55,860 shares of common stock and 119,450 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions by an executive under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Industry Context
Executive stock transactions are common and are often scrutinized by investors to gauge management's confidence in the company's future prospects.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- Rule 10b5-1 plans are a common tool used by executives to manage their stock transactions and avoid insider trading allegations.
- The sale price of $68.2446 is a key metric to compare against industry peers and historical performance.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, depending on the overall market reaction to the news.
Key Dates
| Date | Description |
|---|---|
| March 9, 2024 | Date of adoption of Rule 10b5-1 trading plan |
| March 25, 2019 | Vesting commencement date of stock option |
| April 5, 2019 | Date stock option was granted |
| June 10, 2024 | Date of stock option exercise and sale |
| June 12, 2024 | Date of Form 4 filing |
| April 4, 2029 | Expiration date of stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.